Quanterix Corporation announced publication of a landmark study in the high impact journal JAMA Network Open. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstrated that while individual biomarkers provide a baseline snapshot of pathology, the combination of multiple markers at baseline--along with their subsequent longitudinal trajectoryories-- offers a significantly more comprehensive view of clinical risk.
The research utilized ultra-sensitive Simoa®? technology to measure biomarkers representing the four critical biological axes of Alzheimer's disease: amyloid (Ab42/Ab40 ratio), tau (p-Tau 217), neuroinflammation (GFAP), and neurodegeneration (NfL). This JAMA paper highlights how Quanterix's Simoa®?
ultra-sensitive technology and multiplexed biomarker assays are powering advances in Alzheimer's disease research, which is becoming increasingly focused on evaluating multiple biomarkers and multiple disease pathways. Quanterix is also leading the way in Alzheimer's diagnostics with scalable multi-marker laboratory developed tests, such as LucentAD Complete which is designed with same biomarkers evaluated in the JAMA study. As the company's first algorithmic multi-analyte test for amyloid pathology risk in symptomatic individuals, LucentAD Complete stands alone in providing both an overall amyloid risk score and individual results for these same biomarkers alongside normative reference ranges.
